BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11119899)

  • 1. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation.
    Wang XH; Tang XD; Xu D
    Transplant Proc; 2000 Nov; 32(7):1702-3. PubMed ID: 11119899
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
    Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation.
    Boggi U; Vistoli F; Coppelli A; Marchetti P; Rizzo G; Mosca F
    Transplant Proc; 2001; 33(7-8):3201-2. PubMed ID: 11750373
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA; Bakran A; Brown MW; Grinyo J; Hammad A; Hyatt D; Owens G
    Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
    [No Abstract]   [Full Text] [Related]  

  • 9. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function.
    Liu B; Lin ZB; Ming CS; Zhang WJ; Chen ZS; Sha B; Zeng FJ; Chen S
    Transplant Proc; 2003 Feb; 35(1):87-8. PubMed ID: 12591319
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience.
    Urbizu JM; Amenabar JJ; Gomez-Ullate P; Zarraga S; Lampreabe I
    Transplant Proc; 2002 Feb; 34(1):87-8. PubMed ID: 11959197
    [No Abstract]   [Full Text] [Related]  

  • 13. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug regimens affect cadaveric kidney graft survival.
    Kauffman HM; Cherikh WS; Delmonico FL
    Transplant Proc; 2001; 33(1-2):1029-30. PubMed ID: 11267176
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
    Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
    [No Abstract]   [Full Text] [Related]  

  • 16. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transplant Proc; 1997; 29(1-2):334-6. PubMed ID: 9123027
    [No Abstract]   [Full Text] [Related]  

  • 17. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
    Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
    Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
    [No Abstract]   [Full Text] [Related]  

  • 18. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
    Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
    Wong KM; Cheung CY; Chan YH; Chak WL; Choi KS; Chau KF; Li CS
    Transplant Proc; 2000 Nov; 32(7):1721-2. PubMed ID: 11119907
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral.
    Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K
    Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.